Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

Abstract This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal obser...

Full description

Saved in:
Bibliographic Details
Main Authors: Ji Eun Park, Young‐Ran Yoon, Chang Ho Kim, Jaehee Lee
Format: Artigo
Language:Inglês
Published: Wiley 2022-04-01
Series:Thoracic Cancer
Subjects:
alectinib
ALK rearrangement
lung cancer
M4
pharmacokinetics
Online Access:https://doi.org/10.1111/1759-7714.14357
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items